Royalty Pharma plc
RPRX
Rangering i aksjer
#892
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Aksjekurs
$60.39
Sist synkronisert: 2026-10-19
Markedsverdi
$26.89B
Endring (1 dag)
-0.93%
Endring (1 år)
64.87%
Land
US
Handel Royalty Pharma plc (RPRX)
Kategori
Healthcare
Utbytteavkastning for Royalty Pharma plc (RPRX)
Royalty Pharma plc (aksjesymbol: RPRX) sin utbytteavkastning (TTM) per 2023-12-31 er: 2.85%
Gjennomsnittlig utbytteavkastning de siste 5 årene: 2.37%
Gjennomsnittlig utbytteavkastning de siste 5 årene: 2.37%
Utbytteavkastning for Royalty Pharma plc (RPRX) fra 2015 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
| År | Utbytteavkastning | Endre |
|---|---|---|
| 2026 (TTM) | 1.57% | -52.57% |
| 2024 | 3.31% | 16.14% |
| 2023 | 2.85% | 47.67% |
| 2022 | 1.93% | 11.56% |
| 2021 | 1.73% | -15.61% |
| 2020 | 2.05% | -56.29% |
| 2019 | 4.69% | -9.28% |
| 2018 | 5.17% | 10.94% |
| 2017 | 4.66% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
| Selskap | Utbytteavkastning | Land |
|---|---|---|
| 0.00% |
SE
|
|
| 0.00% |
FR
|
|
| 0.00% |
IT
|
|
| 2.29% |
HK
|
|
| 0.00% |
US
|
